Poll: Vote on the Top GU Cancer Abstracts to Watch at ESMO 2025

The 2025 European Society of Medical Oncology (ESMO) Congress in Berlin, Germany, kicks off on October 17, and this year’s Congress features a notable number of late-breaking abstracts (LBAs) across genitourinary (GU) malignancies.

An interim analysis from the phase 3 RAMPART trial is expected to report on the efficacy of immune checkpoint inhibition after nephrectomy in patients with resected locally advanced renal cell carcinoma (RCC) at intermediate or high risk of recurrence. Updates on investigational combinations for advanced clear cell RCC are expected from substudy 03A of the phase 1/2 KEYMAKER-U03 umbrella trial, which involves regimens based on pembrolizumab (Keytruda).

In bladder cancer, the phase 3 POTOMAC trial is presenting final analysis data for durvalumab (Imfinzi) combined with Bacillus Calmette-Guérin (BCG) for BCG-naive, high-risk non–muscle-invasive bladder cancer (MIBC). Primary analysis and biomarker results from the SunRISe-4 of neoadjuvant gemcitabine intravesical system (Inlexzo; TAR-200) plus cetrelimab or cetrelimab alone in patients with MIBC is also expected.

To find out which LBAs are most important to Targeted Oncology readers, we’re launching a series of polls to identify the most exciting research results coming out of RCC and bladder cancer. Voting is now open on LinkedIn, X, and Facebook, through October 8, 2025.

What Are the Top Abstracts to Watch in RCC at the ESMO 2025 Congress?

Poll 1: Which of these RCC abstracts are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA93 - First results from RAMPART: An international phase 3 randomized-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL

2. LBA94 - LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)

3. LBA95 - Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial

4. LBA96 - First-line pembrolizumab-based regimens for advanced clear cell renal cell carcinoma: KEYMAKER-U03 substudy 03A

What Are the Top Abstract to Watch in Bladder Cancer at the ESMO 2025 Congress?

Poll 2: Which of these bladder cancer abstracts are you most anticipating at ESMO 2025?

Vote Now: LinkedIn | X | Facebook

1. LBA107: ALBAN: A phase 3, randomized, open-label, international study of intravenous (IV) atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naive high-risk, non–muscle-invasive bladder cancer (NMIBC)

2. LBA108 - Durvalumab (D) in combination with BCG for BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomized POTOMAC trial

3. LBA110 - A blinded, exploratory phase 2 trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial

4. LBA112 - Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results

By voting on these polls, you’ll help inform our coverage and bring you the most important news coming out of the ESMO 2025 Congress. The ESMO Congress offers a global oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives to meet, share, and learn about the latest in cancer care, from groundbreaking discoveries to cutting-edge treatments.

Polls are open through DATE. Share these with your peers and colleagues and get the discussion going.